US Stock Movement: Replimune Group surged on October 28th due to TUDRIQEV commercialization and improved performance

Replimune Group October 28 Surge Interpretation

Keywords: TUDRIQEV commercialization, performance improvement

1. On October 28, the company announced financial results for the second quarter of fiscal year 2027: diluted loss per share was $0.54, narrowing from $0.90 in the same period last year.

2. On October 28, the company updated the commercialization progress of TUDRIQEV: On October 6, the drug was used for the first time in advanced melanoma patients, with prescriptions issued by more than 15 institutions; the company has reached out to over 70% of the first batch of 200 key institutions, and stated that its current inventory exceeds one year. Since October 1, TUDRIQEV has been commercially available in the U.S., for combination therapy with nivolumab for certain advanced melanoma cases; the company mainly focuses on novel oncolytic immunotherapies.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)